Jaguar Health Files 8-K: Material Agreements and Equity Sales

Ticker: JAGX · Form: 8-K · Filed: 2025-06-30T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, financial-obligation, equity-sale

TL;DR

Jaguar Health dropped an 8-K detailing new debt and equity sales. Watch closely.

AI Summary

On June 27, 2025, Jaguar Health, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported on unregistered sales of equity securities and amendments to its articles of incorporation or bylaws. This filing details significant corporate actions and financial commitments undertaken by the company.

Why It Matters

This 8-K filing indicates significant corporate actions, including new financial obligations and equity transactions, which could impact the company's financial structure and shareholder value.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements, financial obligations, and unregistered equity sales, which can introduce financial and operational risks.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by Jaguar Health, Inc. on June 27, 2025?

The filing indicates the entry into a material definitive agreement that creates a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant.

What other significant events are reported in this 8-K filing?

The filing also reports on unregistered sales of equity securities and amendments to articles of incorporation or bylaws, or a change in fiscal year.

When was the report filed with the SEC?

The report was filed on June 30, 2025.

What is Jaguar Health, Inc.'s fiscal year end?

Jaguar Health, Inc.'s fiscal year ends on December 31.

What was Jaguar Health, Inc.'s former name?

Jaguar Health, Inc.'s former name was Jaguar Animal Health, Inc., with a date of name change on August 30, 2013.

From the Filing

0001193125-25-152345.txt : 20250630 0001193125-25-152345.hdr.sgml : 20250630 20250630120935 ACCESSION NUMBER: 0001193125-25-152345 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250627 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250630 DATE AS OF CHANGE: 20250630 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Jaguar Health, Inc. CENTRAL INDEX KEY: 0001585608 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36714 FILM NUMBER: 251090146 BUSINESS ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-371-8300 MAIL ADDRESS: STREET 1: 200 PINE STREET SUITE 400 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 FORMER COMPANY: FORMER CONFORMED NAME: Jaguar Animal Health, Inc. DATE OF NAME CHANGE: 20130830 8-K 1 d14926d8k.htm 8-K 8-K false 0001585608 --12-31 0001585608 2025-06-27 2025-06-27     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2025     Jaguar Health, Inc. (Exact name of Registrant as Specified in Its Charter)       Delaware   001-36714   46-2956775 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   200 Pine Street   Suite 400   San Francisco , California   94104 (Address of Principal Executive Offices)   (Zip Code) Registrant’s Telephone Number, Including Area Code: (415) 371-8300 (Former Name or Former Address, if Changed Since Last Report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, Par Value $0.0001 Per Share   JAGX   The Nasdaq Stock Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 1.01 Entry into a Material Definitive Agreement. Royalty Interest for Series M Preferred Stock Exchange Transactions As previously disclosed, on October 8, 2020, Jaguar Health, Inc. (the “Company”) sold to Iliad Research and Trading, L.P. (“Iliad”) a ro

View on Read The Filing